Mereo BioPharma Group plc (FRA:MAH0)

Market Cap	38.10M -83.9%
Revenue (ttm)	n/a
Net Income	-24.60M
EPS	-0.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2320
Previous Close	0.2340
Day's Range	0.2320 - 0.2320
52-Week Range	0.1950 - 1.9550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 39
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MAH0

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error